High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose
François Lefrère, Richard Delarue, Dominique Somme, Vincent Levy, Gandhi Damaj, Angela Tu, Raphael Porcher, Françoise Audat, Claire Boulat, Marine Cavazzana-Calvo, Agnès Buzyn, Coralie Belanger, NatacVolume:
42
Année:
2002
Langue:
english
Pages:
8
DOI:
10.1046/j.1525-1438.2002.00060.x
Fichier:
PDF, 273 KB
english, 2002